In this issue of European Urology, a study by Escudier et al [1] is published. This study builds on the previous publications investigating ipilimumab and nivolumab (IN) in metastatic renal cancer, including 30-month follow-up data [2,3]. The more recent publications show that IN maintains its overall survival (OS) advantage over sunitinib (OS hazard ratio [HR] 0.66 [95% confidence interval {CI} 0.45-0.80]), and there is a significant population that benefits from long-term remission. Finally, clinical benefit is broadly limited to patients with International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) intermediate- and poor-risk disease.